123 related articles for article (PubMed ID: 7740454)
1. In vitro mutagenesis study of two critical glutamic acids in the calcium binding loop of the factor IX heavy chain.
Hamaguchi N; Stafford D
Thromb Haemost; 1994 Dec; 72(6):856-61. PubMed ID: 7740454
[TBL] [Abstract][Full Text] [Related]
2. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
3. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
[TBL] [Abstract][Full Text] [Related]
4. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
Lin SW; Lin CN; Hamaguchi N; Smith KJ; Shen MC
Blood; 1994 Sep; 84(6):1866-73. PubMed ID: 7915915
[TBL] [Abstract][Full Text] [Related]
6. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
[TBL] [Abstract][Full Text] [Related]
7. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation.
Sinha D; Marcinkiewicz M; Navaneetham D; Walsh PN
Biochemistry; 2007 Aug; 46(34):9830-9. PubMed ID: 17676929
[TBL] [Abstract][Full Text] [Related]
8. Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene.
Reijnen MJ; Maasdam D; Bertina RM; Reitsma PH
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):341-8. PubMed ID: 8075306
[TBL] [Abstract][Full Text] [Related]
9. Factor IX Chongqing: a new mutation in the calcium-binding domain of factor IX resulting in severe hemophilia B.
Wang NS; Zhang M; Thompson AR; Chen SH
Thromb Haemost; 1990 Feb; 63(1):24-6. PubMed ID: 2339358
[TBL] [Abstract][Full Text] [Related]
10. Modeling human zymogen factor IX.
Perera L; Darden TA; Pedersen LG
Thromb Haemost; 2001 Apr; 85(4):596-603. PubMed ID: 11341491
[TBL] [Abstract][Full Text] [Related]
11. Substrate-dependent modulation of the mechanism of factor XIa inhibition.
Pedicord DL; Seiffert D; Blat Y
Biochemistry; 2004 Sep; 43(37):11883-8. PubMed ID: 15362874
[TBL] [Abstract][Full Text] [Related]
12. Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein.
Atoda H; Ishikawa M; Mizuno H; Morita T
Biochemistry; 1998 Dec; 37(50):17361-70. PubMed ID: 9860851
[TBL] [Abstract][Full Text] [Related]
13. Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
Maekawa H; Sugo T; Yamashita N; Kamiya K; Umeyama H; Miura N; Naka H; Nishimura T; Yoshioka A; Matsuda M
Biochemistry; 1993 Jun; 32(24):6146-51. PubMed ID: 8512923
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of factor IX: defects in haemophilia B.
McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
[TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of human factor IX. Factor IXthr-397 and factor IXval-397.
Hamaguchi N; Charifson PS; Pedersen LG; Brayer GD; Smith KJ; Stafford DW
J Biol Chem; 1991 Aug; 266(23):15213-20. PubMed ID: 1907972
[TBL] [Abstract][Full Text] [Related]
16. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
[TBL] [Abstract][Full Text] [Related]
17. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition.
Kolkman JA; Mertens K
Biochem J; 2000 Sep; 350 Pt 3(Pt 3):701-7. PubMed ID: 10970782
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of coagulation factor IX-binding protein from habu snake venom at 2.6 A: implication of central loop swapping based on deletion in the linker region.
Mizuno H; Fujimoto Z; Koizumi M; Kano H; Atoda H; Morita T
J Mol Biol; 1999 May; 289(1):103-12. PubMed ID: 10339409
[TBL] [Abstract][Full Text] [Related]
19. Activation of factor IX by factor XIa--a spectrophotometric assay for factor IX in human plasma.
Tans G; Janssen-Claessen T; van Dieijen G; Hemker HC; Rosing J
Thromb Haemost; 1982 Oct; 48(2):127-32. PubMed ID: 6983739
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.
Chung KS; Madar DA; Goldsmith JC; Kingdon HS; Roberts HR
J Clin Invest; 1978 Nov; 62(5):1078-85. PubMed ID: 711853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
